Tag: D-CyBorD

Innovation, Research

Biologic Effective in Light Chain Amyloidosis

June 16, 2020

Via: MedPageToday

Adding the anti-CD38 agent daratumumab (Darzalex) to cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) improved the rate of hematologic complete response and delayed the time to major organ deterioration progression-free survival (MOD-PFS) compared with CyBorD in patients with newly diagnosed light chain […]